Copyright Reports & Markets. All rights reserved.

Global Parkinson Disease Drug Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Parkinson Disease Drug Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Sinemet-CR
      • 1.4.3 Trastal
      • 1.4.4 Madopar
      • 1.4.5 COMT Inhibitor
      • 1.4.6 Other
    • 1.5 Market by Application
      • 1.5.1 Global Parkinson Disease Drug Market Share by Application (2014-2025)
      • 1.5.2 Under 40 Years Old
      • 1.5.3 40-65 Years Old
      • 1.5.4 Above 65 Years Old
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Parkinson Disease Drug Market Size
    • 2.2 Parkinson Disease Drug Growth Trends by Regions
      • 2.2.1 Parkinson Disease Drug Market Size by Regions (2014-2025)
      • 2.2.2 Parkinson Disease Drug Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Parkinson Disease Drug Market Size by Manufacturers
      • 3.1.1 Global Parkinson Disease Drug Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Parkinson Disease Drug Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Parkinson Disease Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Parkinson Disease Drug Key Players Head office and Area Served
    • 3.3 Key Players Parkinson Disease Drug Product/Solution/Service
    • 3.4 Date of Enter into Parkinson Disease Drug Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Parkinson Disease Drug Market Size by Type (2014-2019)
    • 4.2 Global Parkinson Disease Drug Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Parkinson Disease Drug Market Size (2014-2019)
    • 5.2 Parkinson Disease Drug Key Players in United States
    • 5.3 United States Parkinson Disease Drug Market Size by Type
    • 5.4 United States Parkinson Disease Drug Market Size by Application

    6 Europe

    • 6.1 Europe Parkinson Disease Drug Market Size (2014-2019)
    • 6.2 Parkinson Disease Drug Key Players in Europe
    • 6.3 Europe Parkinson Disease Drug Market Size by Type
    • 6.4 Europe Parkinson Disease Drug Market Size by Application

    7 China

    • 7.1 China Parkinson Disease Drug Market Size (2014-2019)
    • 7.2 Parkinson Disease Drug Key Players in China
    • 7.3 China Parkinson Disease Drug Market Size by Type
    • 7.4 China Parkinson Disease Drug Market Size by Application

    8 Japan

    • 8.1 Japan Parkinson Disease Drug Market Size (2014-2019)
    • 8.2 Parkinson Disease Drug Key Players in Japan
    • 8.3 Japan Parkinson Disease Drug Market Size by Type
    • 8.4 Japan Parkinson Disease Drug Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Parkinson Disease Drug Market Size (2014-2019)
    • 9.2 Parkinson Disease Drug Key Players in Southeast Asia
    • 9.3 Southeast Asia Parkinson Disease Drug Market Size by Type
    • 9.4 Southeast Asia Parkinson Disease Drug Market Size by Application

    10 India

    • 10.1 India Parkinson Disease Drug Market Size (2014-2019)
    • 10.2 Parkinson Disease Drug Key Players in India
    • 10.3 India Parkinson Disease Drug Market Size by Type
    • 10.4 India Parkinson Disease Drug Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Parkinson Disease Drug Market Size (2014-2019)
    • 11.2 Parkinson Disease Drug Key Players in Central & South America
    • 11.3 Central & South America Parkinson Disease Drug Market Size by Type
    • 11.4 Central & South America Parkinson Disease Drug Market Size by Application

    12 International Players Profiles

    • 12.1 Merck
      • 12.1.1 Merck Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Parkinson Disease Drug Introduction
      • 12.1.4 Merck Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.1.5 Merck Recent Development
    • 12.2 Akorn
      • 12.2.1 Akorn Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Parkinson Disease Drug Introduction
      • 12.2.4 Akorn Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.2.5 Akorn Recent Development
    • 12.3 GSK
      • 12.3.1 GSK Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Parkinson Disease Drug Introduction
      • 12.3.4 GSK Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.3.5 GSK Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Parkinson Disease Drug Introduction
      • 12.4.4 Novartis Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Boehringer Ingelheim
      • 12.5.1 Boehringer Ingelheim Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Parkinson Disease Drug Introduction
      • 12.5.4 Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.5.5 Boehringer Ingelheim Recent Development
    • 12.6 Teva Pharmaceutical
      • 12.6.1 Teva Pharmaceutical Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Parkinson Disease Drug Introduction
      • 12.6.4 Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.6.5 Teva Pharmaceutical Recent Development
    • 12.7 Abbvie
      • 12.7.1 Abbvie Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Parkinson Disease Drug Introduction
      • 12.7.4 Abbvie Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.7.5 Abbvie Recent Development
    • 12.8 Kyowa Hakko Kirin Pharma
      • 12.8.1 Kyowa Hakko Kirin Pharma Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Parkinson Disease Drug Introduction
      • 12.8.4 Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.8.5 Kyowa Hakko Kirin Pharma Recent Development
    • 12.9 Astellas Pharma
      • 12.9.1 Astellas Pharma Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Parkinson Disease Drug Introduction
      • 12.9.4 Astellas Pharma Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.9.5 Astellas Pharma Recent Development
    • 12.10 Desitin Arzneimittel
      • 12.10.1 Desitin Arzneimittel Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Parkinson Disease Drug Introduction
      • 12.10.4 Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2014-2019)
      • 12.10.5 Desitin Arzneimittel Recent Development
    • 12.11 Endo Pharmaceuticals
    • 12.12 F.Hoffmann-La Roche
    • 12.13 H.Lundbeck
    • 12.14 Valeant
    • 12.15 Apokyn
    • 12.16 Orion
    • 12.17 Stada Arzneimittel
    • 12.18 US WorldMeds
    • 12.19 Valeant Pharmaceuticals

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Parkinson Disease Drug market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Parkinson Disease Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Parkinson Disease Drug development in United States, Europe and China.

      The key players covered in this study
      Merck
      Akorn
      GSK
      Novartis
      Boehringer Ingelheim
      Teva Pharmaceutical
      Abbvie
      Kyowa Hakko Kirin Pharma
      Astellas Pharma
      Desitin Arzneimittel
      Endo Pharmaceuticals
      F.Hoffmann-La Roche
      H.Lundbeck
      Valeant
      Apokyn
      Orion
      Stada Arzneimittel
      US WorldMeds
      Valeant Pharmaceuticals

      Market segment by Type, the product can be split into
      Sinemet-CR
      Trastal
      Madopar
      COMT Inhibitor
      Other

      Market segment by Application, split into
      Under 40 Years Old
      40-65 Years Old
      Above 65 Years Old

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Parkinson Disease Drug status, future forecast, growth opportunity, key market and key players.
      To present the Parkinson Disease Drug development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Parkinson Disease Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now